HI
LUMO

HBK Investments’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

HBK Investments’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,263
Closed -$216K – 1139
2017
Q2 		$216K Buy
+3,263
New +$404K ﹤0.01% 875

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

HBK Investments's LUMO Position: Q3 2017 in Review

HBK Investments sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2017, closing a stake of 3,263 shares — an estimated $216K sold.

HBK Investments first reported a position in LUMO in Q2 2017 and held it in 1 quarter. The position peaked at $216K in Q2 2017. 126 funds tracked by Wall St. Rank hold LUMO as of Q3 2017.

  • HBK Investments reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • HBK Investments sold 3,263 Lumos Pharma, Inc. Common Stock shares in Q3 2017, an estimated $216K.
  • HBK Investments first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • HBK Investments's Lumos Pharma, Inc. Common Stock position peaked at $216K in Q2 2017.
  • 126 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2017.

Based on HBK Investments's 13F filing for Q3 2017, filed 14 Nov 2017.